While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab ... Future of Healthcategory Eli ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca has upgraded its annual ... Trading further benefited from sales of type 2 diabetes medicine Farxiga, its most popular-selling drug, soaring by 27 per cent to $1.9billion, and rare ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

More than 400 million people currently suffer from some type of diabetes, a figure that represents 1 in 11 adults worldwide ...